Short-Term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes

Diabetes Care

Volumn 27, Issue 5, 2004, Pages 1028-1032

  Ryan, Edmond A ^a   Imes, Sharleen ^a   Wallace, Clarissa ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; ORAL ANTIDIABETIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DIET THERAPY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; SHORT COURSE THERAPY; TREATMENT PLANNING;

ADMINISTRATION, ORAL; ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; TIME FACTORS;

EID: 2342587418     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.5.1028     Document Type: Article

References (10)

1. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG: The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34:222-234, 1985
2. Yki-Järvinen H: Toxicity of hyperglycaemia in type 2 diabetes. Diabetes Metab Rev 14:S45-S50, 1998
3. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H: Glucose toxicity in β-cells: Type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 52:571-587, 2003
4. Yki-Järvinen H, Esko N, Eero H, Marja-Riitta T: Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. Am J Med 84:185-192, 1988
5. Gormley MJJ, Hadden DR, Woods R, Sheridan B, Andrews WJ: One month's insulin treatment of type II diabetes: the early and medium-term effects following insulin withdrawal. Metabolism 35:1029-1036, 1986
6. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 20:1353-1356, 1997
7. Nathan DM: Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347:1342-1349, 2002
8. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY: Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110:851-860, 2002
9. Hidaka H, Nagulesparan M, Klimes I, Clark R, Sasaki H, Aronoff SL, Vasquez B, Rubenstein AH, Unger RH: Improvement of insulin secretion but not insulin resistance after short term control of plasma glucose in obese type II diabetics. J Clin Endocrinol Metab 54:217-222, 1982
10. Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinck JW, Bierman EL, Porte D Jr: Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 42:222-229, 1976